90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years

Radioimmunotherapy with 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment in patients with follicular lymphoma (FL) demonstrated promising results with a complete remission (CR) rate of 56% and a median progression-free survival (PFS) of 26 months, when initially analyzed after a medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieger, Kathrin, De Filippi, Rosaria, Lindén, Ola, Viardot, Andreas, Hess, Georg, Lerch, Kristina, Neumeister, Peter, Stroux, Andrea, Peuker, Caroline A., Pezzutto, Antonio, Pinto, Antonello, Keller, Ulrich, Scholz, Christian W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913448/
https://www.ncbi.nlm.nih.gov/pubmed/35150296
http://dx.doi.org/10.1007/s00277-022-04781-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913448/
https://www.ncbi.nlm.nih.gov/pubmed/35150296
http://dx.doi.org/10.1007/s00277-022-04781-3

Ejemplares similares